journal
MENU ▼
Read by QxMD icon Read
search

Multiple Sclerosis Journal—Experimental, Translational and Clinical

journal
https://www.readbyqxmd.com/read/30349734/the-topographical-model-of-ms-empirical-evaluation-of-the-recapitulation-hypothesis
#1
Benjamin M Laitman, Karin Cook, Madhuri Fletcher, Stephen C Krieger
Objective: Using the topographical model of multiple sclerosis (MS) to evaluate a longitudinal cohort we (1) test the recapitulation hypothesis, positing that patients' "disease topography" predicts the clinical pattern of disability accumulation; and (2) identify leading indicators of progression. Methods: 10 patients who transitioned from relapsing-remitting MS to secondary progressive MS (SPMS) were evaluated. Neurologic exams were analyzed from relapses, at time of SPMS diagnosis, and most recent visit...
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30327724/corrigendum
#2
(no author information available yet)
[This corrects the article DOI: 10.1177/2055217318787826.].
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30327723/real-world-experience-of-fingolimod-in-patients-with-multiple-sclerosis-ms-fine-an-observational-study-in-the-uk
#3
Gordon Mazibrada, Charlotte Sharples, Ines Perfect
Background: Fingolimod is approved for the treatment of highly active relapsing-remitting multiple sclerosis in Europe. There is limited information on its effectiveness and safety in clinical practice within the UK. Objective: To evaluate retrospectively the effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis who were prescribed fingolimod by UK neurologists within the National Health Service. Methods: This was a multicentre, observational study conducted in the UK...
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30263146/the-effect-of-disease-modifying-therapies-on-cd62l-expression-in-multiple-sclerosis
#4
Margarete Maria Voortman, Paul Greiner, Daniel Moser, Martin Helmut Stradner, Winfried Graninger, Adrian Moser, Bernd Haditsch, Christian Enzinger, Siegrid Fuchs, Franz Fazekas, Johannes Fessler, Michael Khalil
Background: The increasing armamentarium of disease-modifying therapies in multiple sclerosis is accompanied by potentially severe adverse effects. The cell-adhesion molecule CD62L, which facilitates leukocyte extravasation, has been proposed as a predictive marker for treatment tolerability. However, pre-analytical procedures might impact test results, thereby limiting its clinical usability. Whether the immediate analysis of CD62L expression of peripheral blood mononuclear cells can aid treatment decision making is yet unclear...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30186620/pain-in-aqp4-igg-positive-and-mog-igg-positive-neuromyelitis-optica-spectrum-disorders
#5
Susanna Asseyer, Felix Schmidt, Claudia Chien, Michael Scheel, Klemens Ruprecht, Judith Bellmann-Strobl, Alexander U Brandt, Friedemann Paul
Background: Pain is a frequent symptom in aquaporin-4-immunoglobulin-G-positive neuromyelitis optica spectrum disorders (AQP4-IgG-pos. NMOSD). Data on pain in myelin-oligodendrocyte-glycoprotein-immunoglobulin-G autoimmunity with a clinical NMOSD phenotype (MOG-IgG-pos. NMOSD) are scarce. Objective: The objective of this paper is to investigate pain in MOG-IgG-pos. NMOSD, AQP4-IgG-pos. NMOSD and NMOSD without AQP4/MOG-IgG detection (AQP4/MOG-IgG-neg. NMOSD). Methods: Forty-nine MOG-IgG-pos...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30116550/reference-videos-reduce-variability-of-motor-dysfunction-assessments-in-multiple-sclerosis
#6
Marcus D'Souza, Saskia Steinheimer, Jonas Dorn, Cecily Morrison, Jacques Boisvert, Kristina Kravalis, Jessica Burggraaff, Caspar Ep van Munster, Manuela Diederich, Abigail Sellen, Christian P Kamm, Frank Dahlke, Bernard Mj Uitdehaag, Ludwig Kappos
Motor dysfunction, particularly ataxia, is one of the predominant clinical manifestations in patients with multiple sclerosis (MS). Assessment of motor dysfunction suffers from a high variability. We investigated whether the clinical rating of ataxia can be improved through the use of reference videos, covering the spectrum of severity degrees as defined in the Neurostatus-Expanded Disability Status Scale. Twenty-five neurologists participated. The variability of their assessments was significantly lower when reference videos were used (SD = 0...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30116549/differences-in-clinical-features-between-optic-neuritis-in-neuromyelitis-optica-spectrum-disorders-and-in-multiple-sclerosis
#7
Jindapa Srikajon, Sasitorn Siritho, Chanon Ngamsombat, Naraporn Prayoonwiwat, Niphon Chirapapaisan
Background: Optic neuritis (ON) is one of the common manifestations both in neuromyelitis-optica spectrum disorders (NMOSD) and in multiple sclerosis (MS). Objectives: The objective of this paper is to compare clinical presentations, laboratories and imaging findings in ON associated with MS and NMOSD. Methods: A retrospective chart review was performed in patients presenting with ON in 59 NMOSD patients with 72 eyes' involvement and 163 ON attacks, and 20 MS patients with 23 eyes' involvement and 36 ON attacks...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30094057/cerebrospinal-fluid-gap-43-in-early-multiple-sclerosis
#8
U Rot, Å Sandelius, A Emeršič, H Zetterberg, K Blennow
Background/Objective: Novel biomarkers identifying and predicting disease activity in multiple sclerosis (MS) would be valuable for primary diagnosis and as outcome measures for monitoring therapeutic effects in clinical trials. Axonal loss is present from the earliest stages of MS and correlates with disability measures. Growth-associated protein 43 (GAP-43) is a presynaptic protein with induced expression during axonal growth. We hypothesized this protein could serve as a biomarker of axonal regeneration capacity in MS...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30090642/promotion-of-physical-activity-and-exercise-in-multiple-sclerosis-importance-of-behavioral-science-and-theory
#9
REVIEW
Robert W Motl, Dorothy Pekmezi, Brooks C Wingo
There is an obvious disconnect between evidence of benefits and rates of participation in exercise and physical activity among people living with multiple sclerosis (MS). We propose that the problem with exercise behavior in MS (i.e. lack of broad or increasing participation by people with MS despite evidence of meaningful benefits) might be ameliorated through the inclusion of behavior change theory in the design of exercise programs and promotion efforts, as has been undertaken in other populations such as breast cancer survivors...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30090641/objective-and-subjective-measures-of-dalfampridine-efficacy-in-clinical-practice
#10
Sylvia Klineova, Rebecca Farber, Joshua Friedman, Colleen Farrell, Fred D Lublin, Stephen Krieger
Background: Multiple sclerosis affects mobility in over 80% of patients. Dalfampridine is the only approved treatment for walking impairment in multiple sclerosis. We assessed dalfampridine utilization in our practice and investigated response using timed 25 foot walk (T25FW) improvement and a patient-reported ambulation inventory. Methods: Chart review identified patients with multiple sclerosis for whom dalfampridine was prescribed. T25FW data were extracted from medical records...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30090640/costs-and-quality-of-life-by-disability-among-people-with-multiple-sclerosis-a-register-based-study-in-sweden
#11
Hanna Gyllensten, Andrius Kavaliunas, Kristina Alexanderson, Jan Hillert, Petter Tinghög, Emilie Friberg
Background: Population-based estimates of costs of illness and health-related quality of life, by disability levels among people with multiple sclerosis, are lacking. Objectives: To estimate the annual costs of illness and health-related quality of life, by disability levels, among multiple sclerosis patients, 21-64 years of age. Methods: Microdata from Swedish nationwide registers were linked to estimate the prevalence-based costs of illness in 2013, including direct costs (prescription drug use and specialised healthcare) and indirect costs (calculated using sick leave and disability pension), and health-related quality of life (estimated from the EQ-5D)...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30038791/high-prevalence-and-indexes-of-anti-john-cunningham-virus-antibodies-in-a-cohort-of-chinese-patients-with-multiple-sclerosis
#12
Alexander Lau, Wei Qiu, Allan Kermode, Cheryl Au, Angel Ng, Adrian Wong, Sze-Ho Ma, Lisa Au, Karen Ma, Bonaventure Ip, Vincent Mok
We performed a cross-sectional study in 123 Chinese multiple sclerosis patients residing in Hong Kong to evaluate their anti-John Cunningham virus status using STRATIFY JCV DxSelect assays. Anti-John Cunningham virus antibody was present in 98/123 (80%) subjects, among which 75/98 (77%) had an anti-John Cunningham virus index ≥1.5. Anti-John Cunningham virus antibody seropositivity was not correlated with age, disease duration, Expanded Disability Status Scale scores, types of multiple sclerosis (relapsing vs progressive), or disease-modifying treatments used...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30038790/mog-igg-associated-disease-has-a-stereotypical-clinical-course-asymptomatic-visual-impairment-and-good-treatment-response
#13
Lekha Pandit, Sharik Mustafa, Ichiro Nakashima, Toshyuki Takahashi, Kimhiko Kaneko
Objectives: We investigated the clinical characteristics and treatment response in myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-associated disease and looked for evidence of subclinical disease. Methods: We prospectively evaluated the frequency and pattern of relapse, tested afferent visual function and monitored treatment response in 42 south Asian patients from a single centre. Results: Eighteen patients (42.9%) had monophasic and 24 (57...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30038789/dna-methylation-changes-in-cd4-t-cells-isolated-from-multiple-sclerosis-patients-on-dimethyl-fumarate
#14
Vicki E Maltby, Rodney A Lea, Karen A Ribbons, Katherine A Sanders, Daniel Kennedy, Myintzu Min, Rodney J Scott, Jeannette Lechner-Scott
Background: Dimethyl fumarate is an oral treatment for multiple sclerosis, whose mechanism of action is not fully understood. Objective: To investigate the effects of dimethyl fumarate on DNA methylation in the CD4+ T cells of multiple sclerosis patients. Methods: We performed Illumina EPIC arrays to investigate the DNA methylation profiles of CD4+ T cells derived from multiple sclerosis patients before and after dimethyl fumarate treatment...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30090639/cladribine-off-label-disease-modification-for-people-with-multiple-sclerosis-in-resource-poor-settings
#15
Zhifeng Mao, César Álvarez-Gonzalez, Stefania De Trane, Ozlem Yildiz, Christo Albor, Gabriel Doctor, Derek Soon, George Pepper, Benjamin P Turner, Monica Marta, Joela Mathews, Gavin Giovannoni, David Baker, Klaus Schmierer
Background: A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment. Objective: The objective of this commentary is to propose a useful cost-effective disease-modifying treatment option for pwMS in LMIC with potential high efficacy and high convenience to the pwMS and treating physician. Viewpoint : We propose using generic 2-chloro-2'-deoxyadenosine (cladribine), a small molecule licensed for treatment of people with hairy cell leukaemia, as a solution of this significant equity imbalance...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30090638/development-of-a-gait-module-to-complement-the-12-item-multiple-sclerosis-walking-scale-a-mixed-methods-study
#16
Sara Strzok, Sophie Cleanthous, Farrah Pompilus, Stefan J Cano, Patrick Marquis, Stanley Cohan, Myla D Goldman, Kiren Kresa-Reahl, Jennifer Petrillo, Carmen Castrillo-Viguera, Diego Cadavid, Shih-Yin Chen
Background and objective: The 12-item Multiple Sclerosis Walking Scale (MSWS-12) is a patient-reported outcome instrument that quantifies the progressive loss of walking ability from the patient perspective. However, previous psychometric analyses indicated floor and ceiling effects across the multiple sclerosis severity spectrum. This study aimed to address floor effects by creating a gait module that can be used in conjunction with the MSWS-12 for better measurement of treatment benefit in the higher functioning multiple sclerosis population...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/30090637/onset-of-secondary-progressive-multiple-sclerosis-is-not-influenced-by-current-relapsing-multiple-sclerosis-therapies
#17
Francisco Coret, Francisco C Pérez-Miralles, Francisco Gascón, Carmen Alcalá, Arantxa Navarré, Ana Bernad, Isabel Boscá, Matilde Escutia, Sara Gil-Perotin, Bonaventura Casanova
Background: Disease-modifying therapies are thought to reduce the conversion rate to secondary progressive multiple sclerosis. Objective: To explore the rate, chronology, and contributing factors of conversion to the progressive phase in treated relapsing-remitting multiple sclerosis patients. Methods: Our study included 204 patients treated for relapsing-remitting multiple sclerosis between 1995 and 2002, prospectively followed to date. Kaplan-Meier analysis was applied to estimate the time until secondary progressive multiple sclerosis conversion, and multivariate survival analysis with a Cox regression model was used to analyse prognostic factors...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29977589/patient-perceived-changes-in-sexual-dysfunction-after-initiation-of-natalizumab-for-multiple-sclerosis
#18
Derrick Robertson, Angela Aungst, Ryan Collier, Jhulianna Vivar, Natalie Moreo, Lise Casady, Tuan Vu
Purpose: Sexual dysfunction is a common but often overlooked secondary symptom of multiple sclerosis (MS) and can be associated with a decreased health-related quality of life (HRQoL). Natalizumab is a disease-modifying therapy approved for the treatment of relapsing forms of MS. In addition to its efficacy, those using natalizumab have shown improvement in HRQoL parameters, including fatigue and cognition. The idea that improvement in fatigue may also correlate with improvement in sexual dysfunction is the impetus for this study...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29900003/novel-computer-based-testing-shows-multi-domain-cognitive-dysfunction-in-patients-with-multiple-sclerosis
#19
Andrew D Smith, Charles Duffy, Andrew D Goodman
Background: Although cognitive dysfunction is a leading cause of disability and poor quality of life in patients with multiple sclerosis (MS), it is infrequently tested in routine clinical evaluation. Development of a cognitive testing paradigm that captured MS-related cognitive dysfunction and could be obtained in a routine clinical setting may increase surveillance and recognition of cognitive dysfunction. Objectives: This was a pilot study to determine if Cognivue could find cognitive performance differences between patients with MS and healthy controls (HC)...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29854416/relapse-rate-and-mri-activity-in-young-adult-patients-with-multiple-sclerosis-a-post-hoc-analysis-of-phase-3-fingolimod-trials
#20
Jutta Gärtner, Tanuja Chitnis, Angelo Ghezzi, Daniela Pohl, Wolfgang Brück, Dieter Adrian Häring, Goeril Karlsson, Norman Putzki
Background: Disease activity differs in young patients with multiple sclerosis (MS) compared with the overall adult MS population. Objective: The objective of this paper is to evaluate the effect of fingolimod 0.5 mg on disease activity in young adults with MS from three randomized, double-blind Phase 3 trials. Methods: Annualized relapse rate (ARR), number of new/newly enlarging T2 lesions (neT2), and no evidence of disease activity (NEDA-3) were estimated in the intent-to-treat population at age 20 (youngest) and 30 (young) and compared to the overall population...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
journal
journal
52506
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"